BridgeBio Oncology Therapeutics, Inc.
BBOTDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Dec 31, 2026
14wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Acoramidis (AG10)
Amyloid Cardiomyopathy, Transthyretin-Related
Infigratinib 0.25 mg/kg/day
Achondroplasia
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
acoramidis
Amyloidosis
BBT-877
Idiopathic Pulmonary Fibrosis
BBT-207
EGFR Mutant Advanced Non-Small Cell Lung Cancer
PTR-01
Recessive Dystrophic Epidermolysis Bullosa
Infigratinib is provided as a single dose of minitablets for oral administration
Achondroplasia
Infigratinib 0.016 mg/kg
Achondroplasia
AG10
Amyloid Cardiomyopathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acoramidis (AG10) | Phase 3 | Amyloid Cardiomyopathy, Transthyretin-Related | - | - |
Infigratinib 0.25 mg/kg/day | Phase 3 | Achondroplasia | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
acoramidis | Phase 3 | Amyloidosis | - | - |
BBT-877 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
BBT-207 | Phase 2 | EGFR Mutant Advanced Non-Small Cell Lung Cancer | - | - |
PTR-01 | Phase 2 | Recessive Dystrophic Epidermolysis Bullosa | - | - |
Infigratinib is provided as a single dose of minitablets for oral administration | Phase 2 | Achondroplasia | - | - |
Infigratinib 0.016 mg/kg | Phase 2 | Achondroplasia | - | - |
AG10 | Phase 2 | Amyloid Cardiomyopathy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BridgeBio Oncology Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in BridgeBio Oncology Therapeutics, Inc.'s (BBOT) pipeline across Phase 3, Phase 2. Its lead program is Acoramidis (AG10) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BridgeBio Oncology Therapeutics, Inc.'s next FDA catalyst?→
BridgeBio Oncology Therapeutics, Inc.'s (BBOT) next tracked catalyst is a Data Readout expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BBOT biotech catalysts?→
Add BBOT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BridgeBio Oncology Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.